Drug Database
MI

minocycline hydrochloride

✓ Approved

PreCision Dermatology · Small Molecule · Small Molecule

What is minocycline hydrochloride?

minocycline hydrochloride is a small molecule developed by PreCision Dermatology. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyPreCision Dermatology
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, PreCision Dermatology

Therapeutic Indications

minocycline hydrochloride is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsStreptococcal infection✓ Approved

Related Research Articles

PubMedInternational journal of STD & AIDS2026-09-19

Methenamine, minocycline, metronidazole and pristinamycin (M3P) for multi-drug-resistant Mycoplasma genitalium urethritis: A case series.

Vanbaelen Thibaut T, De Baetselier Irith I, Manoharan-Basil Sheeba Santhini SS, Van Den Bossche Dorien D et al.

ObjectivesWorldwide, Mycoplasma genitalium infections are becoming more resistant to both macrolides and fluoroquinolones - termed multi-drug-resistant (MDR) infections. Combination therapy has shown promise in treating other MDR pathogens. We have previously reported the first five cases of MDR M. genitalium urethritis successfully treated with a novel combination therapy regimen consisting of minocycline, metronidazole, methenamine and pristinamycin ('M3P').MethodsWe describe a second case series of four individuals treated with M3P as salvage therapy for M. genitalium urethritis. Clinical data, laboratory findings, resistance profiles, and treatment outcomes were reviewed.ResultsAll four individuals had persistent M. genitalium urethritis and evidence of macrolide and fluoroquinolone resistance. Prior treatments included multiple courses of doxycycline, minocycline, azithromycin, fluoroquinolones, pristinamycin and other salvage regimens. Treatment with M3P for 14 days was associated with complete resolution of symptoms and negative post-treatment M. genitalium nucleic acid amplification tests in all four cases. No adverse effects were reported.ConclusionsM3P is a useful salvage therapy for MDR M. genitalium infections that do not respond to other regimens.

PMID 42762075
Read full article →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-09-19

A decade of decline and regional disparity: Trends and associated factors in use of ritodrine hydrochloride for threatened preterm labor in Japan, a nationwide ecological study.

Yorozu Kazuma K, Hinotsu Shiro S, Matsuura Motoki M, Someya Masayuki M et al.

Ritodrine hydrochloride is a commonly used tocolytic agent for threatened preterm labor in Japan, despite its serious adverse events and limited use in many other countries. National obstetric guidelines have shifted toward restricting its use, but the evidence-practice gap remains unclear. The aim of this study is to determine usage trends for ritodrine at nationwide and prefectural levels and identify factors associated with usage. We conducted an ecological study linking nationwide aggregated medical claims data and statistical survey records across all 47 prefectures. We investigated 10-year trends in ritodrine use from fiscal year (FY) 2014 to 2023. Choropleth maps and spatial statistics illustrated geographic relationships among neighboring prefectures. We also conducted a cross-sectional study to identify factors associated with ritodrine injection use. The usage rate of ritodrine injection per 1000 deliveries decreased by more than 45% over 10 years. Joinpoint regression analysis identified FY2017 as a turning point, after which the decline accelerated. However, prefectural usage varied up to 13.58-fold, with spatial clustering of high-use regions. Factors associated with injection usage included the density of Perinatal Medical Centers (PMCs), hospital admissions for threatened preterm labor and preterm birth per 1000 deliveries, and the proportion of hospitals among delivery facilities. This study showed that nationwide use of ritodrine injection decreased by half over a decade, along with regional disparities among prefectures in Japan. These variations might reflect localized treatment policies influenced by differences in healthcare resources and geographical accessibility.

PMID 42760829
Read full article →
PubMedInfection and drug resistance2026-09-19

Analysis of Antimicrobial Resistance and Infection Characteristics of Myroides odoratimimus Harboring the bla MOC-1 Metallo-β-Lactamase Gene.

Ding Rong R, Xia Guiping G, Tong Huacheng H

To investigate the drug resistance genotype and phenotypic characteristics of a clinical isolate of Myroides odoratimimus producing metallo-β-lactamase, so as to provide reference for the diagnosis and treatment of similar severe infections in critical care settings. A Gram-negative bacillus isolated from blood cultures of an elderly patient with severe bloodstream infection was identified using the Vitek 2 Compact system combined with 16S rRNA gene sequencing. Antimicrobial susceptibility testing was performed using the broth microdilution method to determine minimum inhibitory concentrations (MICs). Metallo-β-lactamase phenotype was identified by the modified carbapenem inactivation method (mCIM) combined with the EDTA-modified carbapenem inactivation method (eCIM). The isolate was identified as Myroides odoratimimus. Both mCIM and eCIM tests were positive, confirming the production of metallo-β-lactamase. Whole-genome sequencing and database comparison revealed the presence of the blaMOC-1 gene in this strain, and PCR amplification followed by sequencing of electrophoretic bands yielded a 629-bp blaMOC-1 sequence. Antimicrobial susceptibility testing showed that the isolate exhibited broad-spectrum resistance and was only susceptible to minocycline, doxycycline, levofloxacin, and cefepime. The patient presented with severe septic shock, showed no response to empirical therapy, developed multiple organ injury, and exhibited abnormally elevated biomarkers of inflammation, metabolism, and cardiovascular function. The findings of this study suggest that the blaMOC-1 gene is carried by this strain and is associated with its broad-spectrum antimicrobial resistance characteristics.

PMID 42761903
Read full article →
PubMedRSC advances2026-09-19

Microwave-induced efficient degradation of tetracycline using magnetic ZnFe2O4 nanoparticles anchored on C/SiO2.

Liu Minghuan M, Ai Shubo S, Wu Wenxin W, Wang Bingqing B et al.

In response to the ecological and health risks posed by Tetracycline Hydrochloride (TCH) residues in the environment, this study develops a microwave-induced catalytic system using ZnFe2O4/C/SiO2 nanocomposites for efficient TCH degradation. The composites were prepared by anchoring ZnFe2O4 nanoparticles onto a rice husk-derived C/SiO2 support, leveraging both the thermal and non-thermal effects of microwave irradiation to synergistically enhance catalytic performance. Our results showed that the porous structure of C/SiO2 effectively dispersed ZnFe2O4 nanoparticles, reduced agglomeration, and significantly improved microwave absorption by balancing dielectric loss and magnetic loss, with a reflection loss reaching -41.97 dB. Under optimized conditions (microwave power: 1000 W, catalyst dosage: 100 mg, reaction time: 21 min), the degradation rate of 60 ppm TCH exceeded 99%. Free radical trapping and EPR analyses confirmed that holes (h+) are the dominant active species responsible for degradation, and oxygen vacancies promote electron-hole separation. Recycling experiments showed that the catalyst maintained a degradation efficiency of over 75% after four cycles, indicating good stability. This study offers an efficient and sustainable microwave catalytic technology for organic wastewater treatment, with the added environmental benefit of utilizing agricultural waste.

PMID 42761882
Read full article →
PubMedJournal of pharmaceutical sciences2026-09-19

Effects of anion excipients on the viscosity of high-concentration mAb solution.

Maruyama Souhei S, Shibuya Risa R, Torisu Tetsuo T, Uchiyama Susumu S

High protein concentrations often lead to high viscosity, necessitating reduced solution viscosity. We investigated the effects of eight anionic excipients commonly used in biopharmaceutical formulations on the solution viscosity of high-concentration monoclonal antibodies using three antibodies with different isoelectric points. The three antibodies exhibited attractive or repulsive protein-protein interaction tendencies in histidine buffer without anionic excipients. The effect of adding anionic excipients on solution viscosity differed by interaction tendencies. Preferential interaction coefficients revealed differences in the extent of interaction between individual anionic excipients and antibodies. Comparison with chloride, positioned in the middle of the Hofmeister series, suggested that the observed viscosity behavior could only be partially explained by the previously reported Hofmeister anion effects on solution viscosity. We examined the effects of combining L-arginine with each anionic excipient as a counter anion. Formulations containing L-arginine and other anionic excipients contributed more strongly to reducing solution viscosity than L-arginine hydrochloride. The effects of anionic excipients on viscosity can be understood in terms of protein-protein interactions of an antibody in the presence of anionic excipients; whether anionic excipients strengthen or weaken the intrinsic protein-protein interactions is important, underscoring the key indicator for selecting the optimal anionic excipients when designing high-concentration formulations with lower viscosities.

PMID 42762895
Read full article →
PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-09-19

Chemical characterization and pharmacological mechanisms of Qizhi Yishen Capsule in early diabetic kidney disease.

Duan Wenna W, Jiang Qiu Q, Shang Guichun G, Liu Jingbo J et al.

This research explored the bioactive components and therapeutic mechanisms of Qizhi Yishen Capsule (QZC) in managing early-stage diabetic kidney disease (DKD) by integrating network pharmacology with experimental evidence, aiming to support its clinical utility with scientific validation. Network pharmacology and molecular docking were utilized to identify QZC's potential targets in DKD treatment. The therapeutic impact of QZC on renal damage in DKD rats was assessed through in vivo tests, including serum biochemistry, histological staining, and transmission electron microscopy analysis.Potential mechanisms were further explored through metabolomics, in vitro experiments, qRT-PCR, and Western blot analysis. The renal protective effects of QZC in DKD were predicted to be mediated via signaling pathways such as PI3K-Akt, AMPK, and MAPK, based on network pharmacology analysis. In vivo studies confirmed that QZC (509 mg·kg-1), in combination with metformin hydrochloride tablets (MET, 104 mg kg-1), significantly alleviated pathological renal injury and improved podocyte ultrastructure in DKD rats. Metabolomics analysis identified 420 candidate biomarkers, of which 157 were upregulated in the DKD model group and downregulated after QZC treatment, and 263 showed the opposite trend. These metabolites were mainly involved in starch and sucrose metabolism, tyrosine metabolism, phenylalanine metabolism, cysteine and methionine metabolism, and the biosynthesis of phenylalanine, tyrosine, and tryptophan. In vitro assays demonstrated that QZC (300 μg ml-1), gamma-linolenic acid (GLA, 12 μmol L-1), and methyl caffeate (MC, 12 μmol L-1)-two active constituents of QZC-significantly inhibited apoptosis in HK-2 cells, regulated the cell cycle, and reduced reactive oxygen species (ROS) levels. qRT-PCR and Western blot analyses indicated that QZC activated AMPK, SIRT1, and PGC-1α expression at the mRNA and protein levels. QZC improves hyperglycemia-induced tubular injury and metabolic disorders in DKD rats by suppressing oxidative stress and apoptosis through multi-component and multi-target regulation of the AMPK/SIRT1/PGC-1α signaling pathway. This study integrates network pharmacology, metabolomics, and experimental validation to systematically elucidate, for the first time, the multi-component basis and the AMPK/SIRT1/PGC-1α pathway mechanism underlying QZC's efficacy against early DKD.

PMID 42762719
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about minocycline hydrochloride